Frank Torti, future FDA chief?

From scientist-in-chief to top chief? Frank Torti, a cancer researcher who joined FDA two months ago, may be in line for the commissioner's job. Beltway wags say the current leader, Andrew von Eschenbach, is likely on his way out after the presidential election in November--no matter who wins. Torti could have the inside track: As scientist in chief, he'd be a logical choice for interim commissioner. And that's how von Eschenbach ended up in the job. Torti's only comment was noncommittal. “I’m not in the habit of taking a job no one’s told me about yet," he told the Pink Sheet. For a peek at his current policy plans, see the RPM Report's link.

- read the RPM Report story
- see the WSJ Health Blog item

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.